

Synthesis of the pentasaccharide hapten from the glycopeptidolipid antigen of *Mycobacterium avium* serovar 12

Zsolt Varga,^a István Bajza,^b Gyula Batta^c and András Lipták^{a,b,*}

^aDepartment of Biochemistry, University of Debrecen, PO Box 55, Debrecen H-4010, Hungary ^bResearch Group for Carbohydrates of the Hungarian Academy of Sciences, PO Box 55, Debrecen H-4010, Hungary ^cResearch Group for Antibiotics of the Hungarian Academy of Sciences, PO Box 70, Debrecen H-4010, Hungary

Received 28 December 2001; revised 28 February 2002; accepted 8 March 2002

Abstract—An effective synthesis of the pentasaccharide hapten from the glycopeptidolipid antigen of *Mycobacterium avium* serovar 12 in the protected *p*-nitrophenyl glycoside, using a 3+2 block synthesis strategy, is described. © 2002 Elsevier Science Ltd. All rights reserved.

Besides *Mycobacterium tuberculosis*¹ and *M. leprae*,^{2,3} the agents of human tuberculosis and leprosy, respectively, another 'atypical' or 'opportunistic' mycobacteria may also cause infections in humans.⁴ Infections with the *M. avium* serocomplex are seen in up to 50% of the patients with AIDS in some areas of the world.^{5–7} The antigens of various serovars of *M. avium* are glycopeptidolipids (GPLs) located in the outer cell surface of these bacteria, whose structures can be described by a general formula⁸ (Fig. 1).

These outer oligosaccharide haptens are responsible for the immunological properties of the bacteria, thus these haptens, after conjugation with suitable proteins, might aid the serodiagnosis of mycobacterial infections. The synthesis of different oligosaccharide haptens and their conjugation to proteins have been recently reviewed.^{8,9}





Keywords: oligosaccharide; glycopeptidolipid; block synthesis; regioselective Zemplén deacylation; *M. avium* serovar 12.

In this paper we report the synthesis of the protected pentasaccharide hapten of the *M. avium* serovar 12^{10} carrying a *p*-nitrophenyl spacer. The structure of the protected hapten **1** is shown in Fig. 2.

The synthesis of the unprotected diastereoisomeric terminal trisaccharides with D- and L-lactamido groups in position 4" was described by van Boom's group¹¹ using 3-aminopropyl as the spacer.

One of the most difficult tasks was the synthesis of the 3-*O*-methyl ether of D-viosamin (4-amino-4,6-dideoxy-D-glucose). Regioselective 3-*O*-methylation of ethyl 2-*O*-benzoyl-1-thio- α -D-fucopyranoside by means of the 3,4-*O*-stannylidene acetal protocol was reported,¹¹ however this procedure did not work in our hands. To overcome these difficulties we started from allyl α -D-fuco-pyranoside¹² **2**, and using the orthoester methodology,¹³ allyl 2,4-di-*O*-benzoyl- α -D-fucopyranoside **3** was obtained in a one-pot three-step reaction sequence (Scheme 1). The 3-OH was then methylated with diazomethane in the presence of BF₃·OEt₂¹⁴ giving **4**.

It is well documented that the isolated 2-O-acyl groups of pyranosides are stable under the conditions of the Zemplén transacylation reaction.^{15–17} Glaudemans et al. showed that an O-acyl group at position 3 was also stable under Zemplén's conditions, when position 2 is deoxygenated and position 4 is blocked.¹⁸ We found that the 2-O-benzoate of **4** is more reactive than the 4-OBz, and could be selectively removed under Zemplén's conditions, and the deacylated product **5** proved to be a useful intermediate. The allyl group was isomer-

0040-4039/02/\$ - see front matter @ 2002 Elsevier Science Ltd. All rights reserved. PII: S0040-4039(02)00491-4

^{*} Corresponding author. Tel.: +36-52-512-913; fax: +36-52-512-913; e-mail: liptaka@tigris.klte.hu





ized to propenyl and then the enol ether was transformed to the 1,2-*O*-propylidene acetal¹⁹ **6**. Compound **6** was treated with equimolar NaOMe to obtain the 4-OH derivative **7**, which was triflated (\rightarrow **8**) and a subsequent nucleophilic displacement with LiN₃ resulted in the D-gluco epimer **9**.

Acid hydrolysis of the propylidene acetal and direct acetylation of the diol formed gave 10 which was

transformed into the trichloroacetimidate **11** using the standard Schmidt procedure.²⁰

The next unit of the pentasaccharide was synthesized from phenyl 2,3-*O*-isopropylidene-1-thio- α -L-rhamnopyranoside 12²¹ by methylation of 4-OH (\rightarrow 13) followed by the hydrolysis of the isopropylidene group (\rightarrow 14) and phase transfer catalyzed selective benzylation²² of the 2-OH (\rightarrow 15). Glycosylation of 15 with the imidate 11 yielded the azido derivative 16 of the terminal disaccharide (Scheme 2).

Our original intent was to use the disaccharide donor **16** for the 2+3 block synthesis of the pentasaccharide. However during the synthesis of an analogous oligosaccharide it was observed²³ that glycosylation of the trisaccharide acceptor **19** with any glycosyl donor failed, but its earlier synthesized²⁴ disaccharide part **20** reacted readily under various glycosylation conditions (Fig. 3).



Figure 3.



Scheme 1. (a) *i*. PhC(OEt)₃, CSA, MeCN; *ii*. BzCl, pyridine; *iii*. AcOH/H₂O, 72% for three steps; (b) CH₂N₂, BF₃·Et₂O, 84%; (c) NaOMe, MeOH, 87% (d) *i*. (Ph₃P)₃RhCl, DABCO, EtOH-toluene-H₂O; *ii*. CSA, CH₂Cl₂, 52% for two steps; (e) NaOMe, MeOH; quant. (f) Tf₂O, pyridine; (g) LiN₃, DMF, 81% for two steps; (h) *i*. TFA, H₂O, CH₂Cl₂; *ii*. Ac₂O, pyridine, 60% for two steps; (i) *i*. hydrazine acetate, DMF; *ii*. CCl₃CN, K₂CO₃, CH₂Cl₂, 91% for two steps.



Scheme 2. (a) MeI, KOH, DMF, 90%; (b) CF₃COOH, H₂O, CH₂Cl₂, 98%; (c) BzlBr, NaOH, Bu₄NBr, CH₂Cl₂-H₂O, 89%; (d) TMSOTf, CH₂Cl₂, -40° C, 63%; (e) NBS, aq. acetone, 83%; (f) CCl₃CN, K₂CO₃, CH₂Cl₂, quantitative.



Scheme 3. (a) TMSOTf, CH₂Cl₂, -60°C, 74%; (b) NIS/TfOH, CH₂Cl₂-THF, -50°C, 50%.

Based on these experiences the thioglycoside 16 was treated with NBS in aqueous acetone²⁵ to yield the hemiacetal 17 which was then converted into imidate 18 (Scheme 2).

Glycosylation of ethyl 2,4-di-*O*-benzyl-1-thio- α -Lrhamnopyranoside 21^{26} with 18 afforded the trisaccharide-type glycosyl donor 22. The dimer 20 was glycosylated with this trisaccharide under NIS/TfOH²⁷ promotion to give the fully protected pentasaccharide 1

Table 1. Selected NMR data of pentasaccharide 1 (δ , ppm)

Residue		$^{1}\mathrm{H}$	¹³ C
A	1	5.58	98.40
	2	4.17	76.21
	3	4.53	72.02
	4	4.18	71.02
	5	3.95	67.53
	CH_3	1.23	15.47
	$J_{\rm C1,H1}$	176.5 Hz	
В	1	4.97	95.07
	2	3.75	78.17
	3	3.87	78.17
	4	3.52	80.29
	5	3.83	68.63
	CH ₃	1.23	17.89
	$J_{\rm C1,H1}$	171.3 Hz	
С	1	4.94	99.20
	2	3.66	78.88
	3	4.01	78.88
	4	3.43	80.29
	5	3.70	68.63
	CH_3	1.07	17.89
	$J_{\rm C1,H1}$	172.7 Hz	
D	1	4.94	100.65
	2	3.72	78.59
	3	3.80	79.89
	4	3.16	81.97
	5	3.62	68.63
	CH_3	1.12	17.89
	OCH ₃	3.38	60.75
	$J_{\rm C1,H1}$	173.0 Hz	
Ε	1	4.47	101.50
	2	4.91	73.25
	3	3.18	83.40
	4	3.00-3.06	66.72
	5	3.00-3.06	70.37
	CH_3	1.05	18.28
	OCH ₃	3.48	60.01
	$J_{\rm C1,H1}$	163	.9 Hz

stereoselectively, which was isolated in 50% yield (Scheme 3).

The structures of all intermediates and the end-product were unambiguously confirmed by one and two dimensional ¹H and ¹³C NMR spectroscopic methods. Selected NMR data (CD₃OD, Bruker DRX 500) for **1** is given in Table 1.

In conclusion, we have elaborated a new procedure for the synthesis of the precursor of the terminal 4-amino-4,6-dideoxy-3-O-methyl-D-glucose (3-O-methyl-Dviosamine); observed and used a new type of the anomalous Zemplén deacylation; verified our earlier observation concerning the very low reactivity of 3"-OH of the **19** trisaccharide acceptor. The 3'-OH of the L-rhamnosyl unit in the disaccharide acceptor **20** showed acceptable reactivity to achieve the synthesis of the fully protected target pentasaccharide **1** using a 3+2 block synthesis.

Acknowledgements

We thank the Howard Hughes Medical Institute and the National Research Foundation (OTKA T035128) for financial support.

References

- Daffé, M.; Lacave, C.; Lanéelle, M.-A.; Lanéelle, G. Eur. J. Biochem. 1987, 167, 155–160.
- 2. Hunter, S. W.; Brennan, P. J. J. Bacteriol. 1981, 147, 728-735.
- Hunter, S. W.; Fujiwara, T.; Brennan, P. J. J. Biol. Chem. 1982, 257, 15072–15078.
- 4. Wolinsky, E. Am. Rev. Respir. Dis. 1979, 119, 107-159.
- Wolinsky, E.; Schaefer, W. B. Int. J. Syst. Bacteriol. 1973, 23, 102–183.
- 6. Good, R. C. Annu. Rev. Microbiol. 1985, 39, 347-369.
- 7. Blaser, M. J.; Cohn, D. L. Rev. Infect. Dis. 1986, 8, 21-30.
- Lipták, A.; Borbás, A.; Bajza, I. Rev. Med. Res. 1994, 14, 307–352.
- 9. Aspinall, G. O.; Chatterjee, D.; Brennan, P. J. Adv. Carbohydr. Chem. Biochem. 1995, 51, 169–242.

- Bozic, C. M.; McNeil, M.; Chatterjee, D.; Jardines, I.; Brennan, P. J. J. Biol. Chem. 1988, 263, 14984– 14991.
- Zegelaar-Jaarsveld, K.; van der Plas, S. C.; van der Marel, G. A.; van Boom, J. H. J. Carbohydr. Chem. 1996, 15, 591–610.
- 12. Garegg, P. J.; Norberg, T. Carbohydr. Res. 1976, 52, 235–240.
- 13. Oscarson, S.; Szönyi, M. J. Carbohydr. Chem. 1989, 8, 663–668.
- Mastronardi, J. O.; Flametti, S. M.; Deferrari, J. O.; Gros, E. G. Carbohydr. Res. 1966, 3, 177–183.
- 15. Lipták, A.; Szurmai, Z.; Nánási, P.; Neszmélyi, A. Carbohydr. Res. 1982, 99, 13–21.
- Szurmai, Z.; Kerékgyártó, J.; Harangi, J.; Lipták, A. Carbohydr. Res. 1987, 164, 313–325.
- 17. Szurmai, Z.; Lipták, A.; Snatzke, G. Carbohydr. Res. 1990, 200, 201–208.

- Petraková, E.; Glaudemans, C. P. J. Carbohydr. Res. 1995, 268, 135–141.
- Gigg, R.; Warren, C. D. J. Chem. Soc. (C) 1968, 1903– 1911.
- 20. Schmidt, R. R.; Michel, J. Angew. Chem. 1980, 92, 763-764.
- 21. Pozsgay, V. Carbohydr. Res. 1992, 235, 295-302.
- 22. Pozsgay, V. Carbohydr. Res. 1979, 69, 284-286.
- 23. Varga, Z.; Bajza, I.; Batta, G.; Lipták, A. *Tetrahedron Lett.* **2001**, *42*, 5283–5286.
- Kerékgyártó, J.; Szurmai, Z.; Lipták, A. Carbohydr. Res. 1993, 245, 65–80.
- 25. Motawia, S. M.; Marcussen, J.; Møller, L. J. Carbohydr. Chem. 1995, 14 (9), 1279–1294.
- Bajza, I.; Kerékgyártó, J.; Hajkó, J.; Szilágyi, L.; Lipták, A. *Carbohydr. Res.* **1994**, *253*, 111–120.
- 27. Veeneman, G. H.; van Leeuwen, S. H.; van Boom, J. H. Tetrahedron Lett. **1990**, *31*, 1331–1334.